Vanguard realignment leaves Utah Medical Products (UTMD) with 0% stake
Rhea-AI Filing Summary
Utah Medical Products Inc received Amendment No. 2 to a Schedule 13G/A from The Vanguard Group stating that, following an internal realignment effective January 12, 2026, The Vanguard Group reports 0 shares (0%) beneficially owned of the company’s common stock. The filing is signed by Ashley Grim, Head of Global Fund Administration on March 27, 2026, and cites SEC Release No. 34-39538 as the basis for disaggregated reporting by Vanguard subsidiaries.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings; reported beneficial ownership is zero.
The filing states The Vanguard Group, after an internal realignment on January 12, 2026, will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The Schedule 13G/A amendment reports 0 shares (0%) beneficially owned in Utah Medical Products.
Cash‑flow treatment and any holdings by specific Vanguard subsidiaries are not detailed in the excerpt; subsequent filings by those subsidiaries could show separate positions.
Amendment aligns reporting with an SEC disaggregation release.
The disclosure cites the January 12, 1998 SEC release permitting disaggregated reporting when internal business units report separately. The amendment documents that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries or divisions.
Regulatory implication: the amendment is procedural and asserts compliance with the cited SEC release; no enforcement action or allegation is stated in the excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.